Elias Jabbour, MD, University of Texas MD Anderson Cancer Center, Houston, TX, comments on how the treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has transformed over the years with novel therapeutic agents. Dr Jabbour also shares some updates from a study evaluating the efficacy of blinatumomab in combination with ponatinib in patients with Ph+ ALL. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.